Literature DB >> 20085485

Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production.

Philip D Minor1.   

Abstract

Influenza virus changes constantly, making vaccine production challenging. Changing the growth substrate from eggs to cell culture raises issues at all stages of the process, from surveillance to the assay of vaccines. The pandemic threat-first H5N1, then H1N1-encouraged a review of methods and brought issues into sharp relief.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20085485     DOI: 10.1086/650171

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

Review 1.  Clinical applications of DNA vaccines: current progress.

Authors:  Bernadette Ferraro; Matthew P Morrow; Natalie A Hutnick; Thomas H Shin; Colleen E Lucke; David B Weiner
Journal:  Clin Infect Dis       Date:  2011-08-01       Impact factor: 9.079

2.  The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses.

Authors:  Natalie Pica; Arun Iyer; Irene Ramos; Nicole M Bouvier; Ana Fernandez-Sesma; Adolfo García-Sastre; Anice C Lowen; Peter Palese; John Steel
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

3.  Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells.

Authors:  Liping Song; He Liu; Shijuan Gao; Wei Jiang; Wenlin Huang
Journal:  J Virol       Date:  2010-06-16       Impact factor: 5.103

4.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

5.  Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants.

Authors:  W Paul Glezen; Manjusha J Gaglani; Claudia A Kozinetz; Pedro A Piedra
Journal:  J Infect Dis       Date:  2010-10-28       Impact factor: 5.226

6.  An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice.

Authors:  Ahmad M Haredy; Nobuyuki Takenaka; Hiroshi Yamada; Yoshihiro Sakoda; Masatoshi Okamatsu; Naoki Yamamoto; Takeshi Omasa; Hisao Ohtake; Yasuko Mori; Hiroshi Kida; Koichi Yamanishi; Shigefumi Okamoto
Journal:  Clin Vaccine Immunol       Date:  2013-05-01

7.  Protease activation mutants elicit protective immunity against highly pathogenic avian influenza viruses of subtype H7 in chickens and mice.

Authors:  Ralf Wagner; Gülsah Gabriel; Matthias Schlesner; Nina Alex; Astrid Herwig; Ortrud Werner; Hans-Dieter Klenk
Journal:  Emerg Microbes Infect       Date:  2013-02-27       Impact factor: 7.163

8.  Host Adaptation and the Alteration of Viral Properties of the First Influenza A/H1N1pdm09 Virus Isolated in Japan.

Authors:  Akira Ainai; Hideki Hasegawa; Masatsugu Obuchi; Takato Odagiri; Makoto Ujike; Masayuki Shirakura; Eri Nobusawa; Masato Tashiro; Hideki Asanuma
Journal:  PLoS One       Date:  2015-06-16       Impact factor: 3.240

9.  Principles underlying rational design of live attenuated influenza vaccines.

Authors:  Yo Han Jang; Baik-Lin Seong
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

10.  Development of high-yield influenza A virus vaccine viruses.

Authors:  Jihui Ping; Tiago J S Lopes; Chairul A Nidom; Elodie Ghedin; Catherine A Macken; Adam Fitch; Masaki Imai; Eileen A Maher; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Nat Commun       Date:  2015-09-02       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.